Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Defined demand scales fast; new paradigms don't. Budget launches accordingly

This season's results split launches into two kinds: those that fill a clear slot and those that must build a market first. Ionis's reset on Tryngolza is the warning.

15 Nov 2026 · CompePharma editorial

Two kinds of launch, two kinds of quarter

Read this batch of third-quarter reports side by side and the divide is not big versus small, or profitable versus loss-making. It is between launches that slot into demand that already exists and launches that must create a new way of treating patients.

The first group had a good quarter. Eton reported record product sales of $57.9 million, up 158% year over year, and said it passed its $200 million annualized run-rate goal five quarters early. It raised 2026 revenue guidance to more than $175 million from more than $145 million, and lifted its adjusted EBITDA target to more than 40%. Iovance posted record revenue of about $122 million, up about 80%, with gross margin around 60%. Keenova raised full-year net sales and adjusted EBITDA guidance on stronger XIAFLEX growth and Acthar Gel strength.

The second group got a reality check. Ionis lowered 2026 Tryngolza product sales guidance because the severe hypertriglyceridemia (sHTG) launch is ramping "more gradually than expected," which the company attributes to "the early dynamics of establishing a new treatment paradigm." That is the most useful sentence in the season, because it names the real constraint: in a large, underserved population, the product is only part of the launch. Prescribers, patients and systems also have to learn a new habit.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →